Make Better Decisions

  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Express Scripts

Generated: December 18, 2017

DrugPatentWatch Database Preview

Details for Patent: 4,594,359

« Back to Dashboard

Summary for Patent: 4,594,359

Title: Pharmaceutical compositions
Abstract:A pharmaceutical composition is described which contains as active ingredient the .beta.-stimulant salbutamol or one or more of its physiologically acceptable salts. The stability of aqueous formulations of the composition is improved by including a cellulose derivative which provide an optically transparent or opalescent colloidal dispersion. Preferred compositions are liquid formulations suitable for oral administration in which the cellulose derivative also serves as a thickening agent.
Inventor(s): Padfield; John M. (Meldreth, GB), Groom; Cheryl V. (Barnard Castle, GB)
Assignee: Glaxo Group Limited (London, GB2)
Application Number:06/593,432
Patent Claim Types:
see list of patent claims
Composition; Compound; Dosage form;

No matches for this query

Foreign Priority and PCT Information for Patent: 4,594,359

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
United Kingdom8215502May 27, 1982

International Patent Family for Patent: 4,594,359

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Austria390191► Subscribe
AustriaA195283► Subscribe
Australia1503983► Subscribe
Australia567675► Subscribe
Belgium896870► Subscribe
Canada1203176► Subscribe
Switzerland656308► Subscribe
Germany3319356► Subscribe
Denmark167558► Subscribe
Denmark241783► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Cantor Fitzgerald
US Department of Justice
Federal Trade Commission

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch: